董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Yang | 男 | Director | 72 | 6.91万美元 | 未持股 | 2021-03-01 |
| Philip Eykerman | 男 | Director | 52 | 6.41万美元 | 未持股 | 2021-03-01 |
| Lisa Qi | 女 | Director | 49 | 4.00万美元 | 未持股 | 2021-03-01 |
| James McCann | 男 | Director | 69 | 6.60万美元 | 未持股 | 2021-03-01 |
| Julie Spencer Washington | 女 | Director | 55 | 3.70万美元 | 未持股 | 2021-03-01 |
| John Melo | 男 | Director, President and Chief Executive Officer | 55 | 134.49万美元 | 未持股 | 2021-03-01 |
| Geoffrey Duyk | 男 | Interim Board Chairman | 61 | 10.77万美元 | 未持股 | 2021-03-01 |
| Carole Piwnica | 女 | Director | 63 | 7.86万美元 | 未持股 | 2021-03-01 |
| L. John Doerr | 男 | Director | 69 | 7.31万美元 | 未持股 | 2021-03-01 |
| Frank Kung | 男 | Director | 72 | 6.41万美元 | 未持股 | 2021-03-01 |
| Steven R. Mills | 男 | Director | 65 | 9.35万美元 | 未持股 | 2021-03-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Han Kieftenbeld | 男 | Chief Financial Officer and Chief Administration Officer | 55 | 175.00万美元 | 未持股 | 2021-03-01 |
| Eduardo Alvarez | 男 | Chief Operating Officer | 57 | 168.43万美元 | 未持股 | 2021-03-01 |
| Nicole Kelsey | 女 | General Counsel and Secretary | 54 | 73.01万美元 | 未持股 | 2021-03-01 |
| John Melo | 男 | Director, President and Chief Executive Officer | 55 | 134.49万美元 | 未持股 | 2021-03-01 |
董事简历
中英对照 | 中文 | 英文- Patrick Yang
-
Patrick Yang，他一直担任我们董事会的成员（2014年7月以来）。他曾担任F. Hoffmann-La Roche Ltd（Roche）的执行副总裁兼全球技术运营主管，在那里他曾负责Roche公司的制药和生物技术生产运营、过程开发、质量、管理、供应管理和分销职能。加入Roche公司之前，他曾任职Genentech公司，在那里他最近担任执行副总裁，负责产品运营，也曾负责制造、过程开发、质量、法规事务和分销职能。加入Genentech Inc.之前，他曾任职Merck & Co.，在那里他曾担任一些领导职务，包括负责亚洲/太平洋制造业务的副总裁，以及供应链管理副总裁。他此前也曾任职General Electric Co.、Life Systems公司。
Patrick Yang is Executive Vice Chairman of National Resilience, Inc., a biomanufacturing company. He is a biotech industry consultant. He previously served as Executive Vice President of Juno Therapeutics, Inc. acquired by Bristol-Myers Squibb, a biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer, from September 2017 to January 2019. From January 2010 through March 2013 Dr. Yang served as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche Ltd. “Roche”, where he was responsible for Roche’s pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management and distribution functions. Before joining Roche, Dr. Yang worked for Genentech Inc., where he served as Executive Vice President of Product Operations, and was responsible for manufacturing, process development, quality, regulatory affairs and distribution functions. Prior to joining Genentech Inc., Dr. Yang worked for Merck & Co., where he held several leadership roles including Vice President of Asia/Pacific Manufacturing Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang currently serves on the boards of directors of Codexis, Inc., PharmaEssentia Corporation and Sana Biotechnology, Inc., and previously served on the boards of directors of Andeavor formerly Tesoro Corporation from December 2010 to September 2018 and Celladon Corporation from March 2014 until May 2015. - Patrick Yang，他一直担任我们董事会的成员（2014年7月以来）。他曾担任F. Hoffmann-La Roche Ltd（Roche）的执行副总裁兼全球技术运营主管，在那里他曾负责Roche公司的制药和生物技术生产运营、过程开发、质量、管理、供应管理和分销职能。加入Roche公司之前，他曾任职Genentech公司，在那里他最近担任执行副总裁，负责产品运营，也曾负责制造、过程开发、质量、法规事务和分销职能。加入Genentech Inc.之前，他曾任职Merck & Co.，在那里他曾担任一些领导职务，包括负责亚洲/太平洋制造业务的副总裁，以及供应链管理副总裁。他此前也曾任职General Electric Co.、Life Systems公司。
- Patrick Yang is Executive Vice Chairman of National Resilience, Inc., a biomanufacturing company. He is a biotech industry consultant. He previously served as Executive Vice President of Juno Therapeutics, Inc. acquired by Bristol-Myers Squibb, a biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer, from September 2017 to January 2019. From January 2010 through March 2013 Dr. Yang served as Executive Vice President and Global Head of Technical Operations for F. Hoffmann-La Roche Ltd. “Roche”, where he was responsible for Roche’s pharmaceutical and biotech manufacturing operations, process development, quality, regulatory, supply management and distribution functions. Before joining Roche, Dr. Yang worked for Genentech Inc., where he served as Executive Vice President of Product Operations, and was responsible for manufacturing, process development, quality, regulatory affairs and distribution functions. Prior to joining Genentech Inc., Dr. Yang worked for Merck & Co., where he held several leadership roles including Vice President of Asia/Pacific Manufacturing Operations and Vice President of Supply Chain Management. He also previously worked at General Electric Co. and Life Systems, Inc. Dr. Yang currently serves on the boards of directors of Codexis, Inc., PharmaEssentia Corporation and Sana Biotechnology, Inc., and previously served on the boards of directors of Andeavor formerly Tesoro Corporation from December 2010 to September 2018 and Celladon Corporation from March 2014 until May 2015.
- Philip Eykerman
-
Philip Eykerman，于2014年3月被任命到我们的董事会，也曾担任DSM公司的执行副总裁，负责公司战略和收购（2011年以来）。他此前曾担任McKinsey & Company Brussels的合伙人（1997年至2011年），负责领导他们在比利时、荷兰、卢森堡和法国的化学物质实践。他是比利时公民。
Philip Eykerman has served as the Executive Vice-President, Corporate Strategy & Acquisitions of Koninklijke DSM N.V. together with its affiliates, “DSM”, a global science-based company in nutrition, health and sustainable living and an entity with which Amyris has a commercial and financial relationship and which is an owner of greater than five percent of the Company’s outstanding common stock, since 2011. In 2015 he was also appointed as a member of the DSM Executive Committee and at present is also responsible for the DSM Food Specialties as well as DSM Hydrocolloids activities. Since September 2020 he is also appointed to President Human Nutrition & Health, thereby now managing/ overseeing all the group’s activities in human nutrition & health while maintaining the responsibility for the DSM Mergers & Acquisitions activities. Next to these roles within DSM, he is also a Supervisory Board member of ChemicaInvest DSM/CVC JV, AnQore TopCo B.V., and AOC Aliancys DSM/CVC JV, and previously served as a member of the Supervisory Board of Patheon N.V. from March 2014 to August 2017. Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 years as a Partner and leader of McKinsey’s Cemicals Practice in the Benelux and France. Before that, he worked as a process/ project engineer for Fluor Daniel. He holds a Master’s degree in Chemical Engineering from the KU Leuven (Belgium), and a Master’s degree in Refinery Engineering from the Institut Francais du Pétrole (France). - Philip Eykerman，于2014年3月被任命到我们的董事会，也曾担任DSM公司的执行副总裁，负责公司战略和收购（2011年以来）。他此前曾担任McKinsey & Company Brussels的合伙人（1997年至2011年），负责领导他们在比利时、荷兰、卢森堡和法国的化学物质实践。他是比利时公民。
- Philip Eykerman has served as the Executive Vice-President, Corporate Strategy & Acquisitions of Koninklijke DSM N.V. together with its affiliates, “DSM”, a global science-based company in nutrition, health and sustainable living and an entity with which Amyris has a commercial and financial relationship and which is an owner of greater than five percent of the Company’s outstanding common stock, since 2011. In 2015 he was also appointed as a member of the DSM Executive Committee and at present is also responsible for the DSM Food Specialties as well as DSM Hydrocolloids activities. Since September 2020 he is also appointed to President Human Nutrition & Health, thereby now managing/ overseeing all the group’s activities in human nutrition & health while maintaining the responsibility for the DSM Mergers & Acquisitions activities. Next to these roles within DSM, he is also a Supervisory Board member of ChemicaInvest DSM/CVC JV, AnQore TopCo B.V., and AOC Aliancys DSM/CVC JV, and previously served as a member of the Supervisory Board of Patheon N.V. from March 2014 to August 2017. Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 years as a Partner and leader of McKinsey’s Cemicals Practice in the Benelux and France. Before that, he worked as a process/ project engineer for Fluor Daniel. He holds a Master’s degree in Chemical Engineering from the KU Leuven (Belgium), and a Master’s degree in Refinery Engineering from the Institut Francais du Pétrole (France).
- Lisa Qi
-
Lisa Qi自2019年5月起担任董事会成员。齐女士是Silver Gift Limited和大凌新潮北京贸易有限公司的创始人兼首席执行官，这两家公司在中国运营大凌家庭电子商务平台。
Lisa Qi has been a member of the Board since May 2019. Ms. Qi is the founder and chief executive officer of Silver Gift Limited and Daling Xinchao Beijing Trading Co., Ltd., which operate the Daling Family e-commerce platform in China. - Lisa Qi自2019年5月起担任董事会成员。齐女士是Silver Gift Limited和大凌新潮北京贸易有限公司的创始人兼首席执行官，这两家公司在中国运营大凌家庭电子商务平台。
- Lisa Qi has been a member of the Board since May 2019. Ms. Qi is the founder and chief executive officer of Silver Gift Limited and Daling Xinchao Beijing Trading Co., Ltd., which operate the Daling Family e-commerce platform in China.
- James McCann
-
James McCann自2019年5月起担任董事会成员。McCann先生是1-800-FLOWERS.COM，Inc.的创始人兼董事会主席，该公司成立于1976年，是一家花卉和美食礼品零售商和分销公司，并于1976年至2016年6月担任1-800-FLOWERS.COM，Inc.的首席执行官。McCann先生还担任国际游戏科技公司公司（前身为GTECH S.p.A.公司和Lottomatica Group S.p.A.公司）和The ScottsMiracle-GroCompany公司的董事。McCann先生此前曾于2004年至2019年5月担任Willis Towers Watson plc（原Willis Group Holdings plc）的董事会成员。
James McCann is the founder and Chairman of the board of directors of 1-800-FLOWERS.COM, Inc., a floral and gourmet foods gift retailer and distribution company founded in 1976 and served as chief executive officer of 1-800-FLOWERS.COM, Inc. from 1976 until June 2016. Mr. McCann also serves on the board of directors of International Game Technology PLC formerly GTECH S.p.A. and Lottomatica Group S.p.A. and has previously served on the board of directors of Willis Towers Watson PLC formerly Willis Group Holdings PLC from 2004 until May 2019 and The Scotts Miracle-Gro Company from 2014 until January 2020. - James McCann自2019年5月起担任董事会成员。McCann先生是1-800-FLOWERS.COM，Inc.的创始人兼董事会主席，该公司成立于1976年，是一家花卉和美食礼品零售商和分销公司，并于1976年至2016年6月担任1-800-FLOWERS.COM，Inc.的首席执行官。McCann先生还担任国际游戏科技公司公司（前身为GTECH S.p.A.公司和Lottomatica Group S.p.A.公司）和The ScottsMiracle-GroCompany公司的董事。McCann先生此前曾于2004年至2019年5月担任Willis Towers Watson plc（原Willis Group Holdings plc）的董事会成员。
- James McCann is the founder and Chairman of the board of directors of 1-800-FLOWERS.COM, Inc., a floral and gourmet foods gift retailer and distribution company founded in 1976 and served as chief executive officer of 1-800-FLOWERS.COM, Inc. from 1976 until June 2016. Mr. McCann also serves on the board of directors of International Game Technology PLC formerly GTECH S.p.A. and Lottomatica Group S.p.A. and has previously served on the board of directors of Willis Towers Watson PLC formerly Willis Group Holdings PLC from 2004 until May 2019 and The Scotts Miracle-Gro Company from 2014 until January 2020.
- Julie Spencer Washington
-
Julie Spencer Washington自2020年1月起担任天主教医疗保健系统Trinity Health的首席营销，传播和客户体验官。她曾于2017年至2019年担任Champion PetFoods的首席营销官，并于2010年至2016年在Jamba Juice担任过许多执行职务，包括首席营销与创新官，在此之前，担任首席品牌官和副总裁，并担任消费产品总经理。在此之前，华盛顿女士曾在Luxottica Retail，Procter&Gamble和Nestlé；Purina担任过多个高级领导职务。她目前是联合研究所和大学的董事会成员。华盛顿女士拥有华盛顿大学的工商管理硕士学位，埃默里大学的化学和心理学文学学士学位以及哈佛大学的驱动数字和社会战略教育高管证书。
Julie Spencer Washington has served as Chief Marketing, Communications & Customer Experience Officer of Trinity Health, a Catholic health care delivery system, since January 2020. She previously served as Chief Marketing Officer of Champion Petfoods from 2017 to 2019 and held a number of executive positions at Jamba Juice from 2010 to 2016 including as Chief Marketing & Innovation Officer and prior to that, as Chief Brand Officer and Vice President and as General Manager, Consumer Products. Prior to that, Ms. Washington served in multiple senior leadership positions at Luxottica Retail, Procter & Gamble and Nestlé Purina. She currently serves on the board of directors of Union Institute & University. Ms. Washington holds a Master of Business Administration degree from Washington University, a Bachelor of Arts degree in Chemistry and Psychology from Emory University, and an Executive in Education Certificate on Driving Digital and Social Strategy from Harvard University. - Julie Spencer Washington自2020年1月起担任天主教医疗保健系统Trinity Health的首席营销，传播和客户体验官。她曾于2017年至2019年担任Champion PetFoods的首席营销官，并于2010年至2016年在Jamba Juice担任过许多执行职务，包括首席营销与创新官，在此之前，担任首席品牌官和副总裁，并担任消费产品总经理。在此之前，华盛顿女士曾在Luxottica Retail，Procter&Gamble和Nestlé；Purina担任过多个高级领导职务。她目前是联合研究所和大学的董事会成员。华盛顿女士拥有华盛顿大学的工商管理硕士学位，埃默里大学的化学和心理学文学学士学位以及哈佛大学的驱动数字和社会战略教育高管证书。
- Julie Spencer Washington has served as Chief Marketing, Communications & Customer Experience Officer of Trinity Health, a Catholic health care delivery system, since January 2020. She previously served as Chief Marketing Officer of Champion Petfoods from 2017 to 2019 and held a number of executive positions at Jamba Juice from 2010 to 2016 including as Chief Marketing & Innovation Officer and prior to that, as Chief Brand Officer and Vice President and as General Manager, Consumer Products. Prior to that, Ms. Washington served in multiple senior leadership positions at Luxottica Retail, Procter & Gamble and Nestlé Purina. She currently serves on the board of directors of Union Institute & University. Ms. Washington holds a Master of Business Administration degree from Washington University, a Bachelor of Arts degree in Chemistry and Psychology from Emory University, and an Executive in Education Certificate on Driving Digital and Social Strategy from Harvard University.
- John Melo
-
John Melo作为全球燃料行业和技术创新领域的企业家和思想领导，John Melo拥有近30年的综合经验。Melo先生自2007年1月起担任Amyris, Inc.的首席执行官和董事，自2008年6月起担任Amyris, Inc.总裁。在加入Amyris之前，Melo先生于1997年至2006年在BP plc（前身为British Petroleum）担任多个高级管理职位，BP plc是世界上最大的能源公司之一，最近担任美国燃料业务总裁。在BP任职期间，Melo先生还担任炼油和营销部门的首席信息官、BP首席执行官Lord Browne的电子商务战略高级顾问和全球品牌发展总监。在加入BP之前，Melo先生曾在会计师事务所Ernst & Young任职，并担任多家初创公司的管理团队成员，包括管理系统集成公司Computer Aided Services和汽车维修软件提供商Alldata Corporation到汽车服务行业。Melo先生目前在Renmatix，Inc.、生物技术创新组织的工业和环境部门以及加州生命科学协会的董事会任职。Melo先生曾被任命为美国-巴西CEO论坛美国部分的成员。
John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as Amyris, Inc. CEO and a director since January 2007 and as Amyris, Inc. President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc formerly British Petroleum, one of the world's largest energy firms, from 1997 to 2006 most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. - John Melo作为全球燃料行业和技术创新领域的企业家和思想领导，John Melo拥有近30年的综合经验。Melo先生自2007年1月起担任Amyris, Inc.的首席执行官和董事，自2008年6月起担任Amyris, Inc.总裁。在加入Amyris之前，Melo先生于1997年至2006年在BP plc（前身为British Petroleum）担任多个高级管理职位，BP plc是世界上最大的能源公司之一，最近担任美国燃料业务总裁。在BP任职期间，Melo先生还担任炼油和营销部门的首席信息官、BP首席执行官Lord Browne的电子商务战略高级顾问和全球品牌发展总监。在加入BP之前，Melo先生曾在会计师事务所Ernst & Young任职，并担任多家初创公司的管理团队成员，包括管理系统集成公司Computer Aided Services和汽车维修软件提供商Alldata Corporation到汽车服务行业。Melo先生目前在Renmatix，Inc.、生物技术创新组织的工业和环境部门以及加州生命科学协会的董事会任职。Melo先生曾被任命为美国-巴西CEO论坛美国部分的成员。
- John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as Amyris, Inc. CEO and a director since January 2007 and as Amyris, Inc. President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc formerly British Petroleum, one of the world's largest energy firms, from 1997 to 2006 most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.
- Geoffrey Duyk
-
Geoffrey Duyk 从2006年5月到2011年5月担任董事会成员。Duyk博士是技术投资公司Circularis Partners的合伙人。2004年至2017年，Duyk博士担任TPG Alternative & Renewable Technologies TPG ART的合伙人兼董事总经理，TPG ART是一家专注于技术的投资公司及其附属公司“TPG”。从1996年到2003年，他在Exelixis, Inc.(一家专注于药物研发的生物制药公司)的董事会任职，并担任研发总裁。在Exelixis之前，从1993年到1996年，Duyk博士是基因组学的副总裁和Millennium Pharmaceuticals的创始科学人员之一。在此之前，Duyk博士是哈佛医学院遗传学系的助理教授和霍华德休斯医学研究所的助理研究员。Duyk博士目前担任Anuvia Plant nutrition的董事会成员;Concentric Ag Corporation临时首席执行官(2019年以来);ReGen Holdings Limited以及非营利的凯斯西储大学董事会成员。他也是莫菲特癌症中心(the Moffitt Cancer Center)的研究所董事会成员，他在那里主持研究和发展委员会。他是OncoBay Clinical的董事会主席，OncoBay Clinical是一家私人合同研究机构(Moffitt Cancer Center的子公司)。Duyk博士是劳伦斯伯克利国家实验室(DOE)的科学顾问委员会成员和Innovatus Capital Partners的顾问委员会成员。此前，2005年8月至2017年6月，Duyk博士曾任职于多个咨询委员会、非营利、私人和上市公司董事会，包括Aerie Pharmaceuticals。他持有Wesleyan University的生物学学士学位、Case Western Reserve University的生物化学博士学位和医学博士学位。
Geoffrey Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies TPG ART, a technology focused investment firm together with its affiliates, "TPG", from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation interim CEO since 2019; and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. He is the Chairman of the board of directors of OncoBay Clinical, a private contract research organization (subsidiary of Moffitt Cancer Center). Dr. Duyk serves as a member of Scientific Advisory Boards for Lawrence Berkeley National Laboratory (DOE) and a member of the Advisory Board of Innovatus Capital Partners. Previously, Dr. Duyk has served on a number of advisory boards, nonprofit, private, and public company boards, including Aerie Pharmaceuticals from August 2005 to June 2017. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University. - Geoffrey Duyk 从2006年5月到2011年5月担任董事会成员。Duyk博士是技术投资公司Circularis Partners的合伙人。2004年至2017年，Duyk博士担任TPG Alternative & Renewable Technologies TPG ART的合伙人兼董事总经理，TPG ART是一家专注于技术的投资公司及其附属公司“TPG”。从1996年到2003年，他在Exelixis, Inc.(一家专注于药物研发的生物制药公司)的董事会任职，并担任研发总裁。在Exelixis之前，从1993年到1996年，Duyk博士是基因组学的副总裁和Millennium Pharmaceuticals的创始科学人员之一。在此之前，Duyk博士是哈佛医学院遗传学系的助理教授和霍华德休斯医学研究所的助理研究员。Duyk博士目前担任Anuvia Plant nutrition的董事会成员;Concentric Ag Corporation临时首席执行官(2019年以来);ReGen Holdings Limited以及非营利的凯斯西储大学董事会成员。他也是莫菲特癌症中心(the Moffitt Cancer Center)的研究所董事会成员，他在那里主持研究和发展委员会。他是OncoBay Clinical的董事会主席，OncoBay Clinical是一家私人合同研究机构(Moffitt Cancer Center的子公司)。Duyk博士是劳伦斯伯克利国家实验室(DOE)的科学顾问委员会成员和Innovatus Capital Partners的顾问委员会成员。此前，2005年8月至2017年6月，Duyk博士曾任职于多个咨询委员会、非营利、私人和上市公司董事会，包括Aerie Pharmaceuticals。他持有Wesleyan University的生物学学士学位、Case Western Reserve University的生物化学博士学位和医学博士学位。
- Geoffrey Duyk previously served on the Board from May 2006 to May 2011. Dr. Duyk is a partner of Circularis Partners, a technology focused investment firm. Previously, Dr. Duyk served as a partner and managing director of TPG Alternative & Renewable Technologies TPG ART, a technology focused investment firm together with its affiliates, "TPG", from 2004 to 2017. Prior to TPG, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of: Anuvia Plant Nutrients; Concentric Ag Corporation interim CEO since 2019; and ReGen Holdings Limited as well as on the nonprofit Case Western Reserve University Board of Trustees. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he chairs the Research and Development committee. He is the Chairman of the board of directors of OncoBay Clinical, a private contract research organization (subsidiary of Moffitt Cancer Center). Dr. Duyk serves as a member of Scientific Advisory Boards for Lawrence Berkeley National Laboratory (DOE) and a member of the Advisory Board of Innovatus Capital Partners. Previously, Dr. Duyk has served on a number of advisory boards, nonprofit, private, and public company boards, including Aerie Pharmaceuticals from August 2005 to June 2017. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and a Ph.D. in Biochemistry and M.D. from Case Western Reserve University.
- Carole Piwnica
-
Carole Piwnica自2009年9月一直是董事会的成员。自2008年1月，Piwnica女士担任纳索斯英国公司的董事，该公司是一家为私人股本给出建议的咨询公司。之前，1996年到2006年Piwnica女士担任Tate & Lyle公共有限公司的董事，2000年到2006年担任政务副主席，该公司是欧洲食品和农业原料公司。1996年到2000年，她成为Amylum Group公司主席，该公司是Tate & Lyle公共有限公司欧洲地区的食品配料公司和分公司。2003年5月到2011年12月，Piwnica女士是英杰华公共有限公司董事会成员，该公司是一家英国保险公司；2006年5月到2009年10月，担任孟山都生物技术咨询委员会的成员；2007年到2010年，成为Dairy Crest董事会成员；1996年到2010年，成为Toepfer Gmbh董事会成员；从2010年到2013年，成为比利时路易斯·德尔海兹零售（比利时）的董事会成员。2010年，她被任命为欧洲通信卫星公司（卫星、法国）和赛诺菲（药品、法国）的董事会成员。Piwnica女士获得布鲁塞尔大学法律学士学位和纽约大学法律硕士学位。自1985年她也成为美国纽约州律师协会的成员，1988年到2013年又成为法国巴黎律师协会的成员。根据她的跨国企业领导的经验和丰富的法律经验和公司管理经验，Piwnica女士在领导跨国农业加工企业中有助于管理团队和董事会，能够合理履行公司管理义务并作出最佳的表现。
Carole Piwnica,Since 2018Managing Partner of Naxos S.A. Switzerland.2007- 2018Founder Director of Naxos UK Ltd United Kingdom.2003-2011Director, Chairwoman of the Corporate Responsibility Committee and member of the Compensation Committee of Aviva PlcUnited Kingdom.2007-2010Director of Dairy Crest PlcUnited Kingdom.1996-2010Director of Toepfer GmbH Germany.2006-2009Member of the Ethical Committee of Monsanto United States.2000-2006Chairwoman of the Export Commission and director of the Association Nationale des Industries Alimentaires (ANIA).2000-2006Director and Vice-Chairwoman of Tate & Lyle Plc for Governmental Affairs (United Kingdom).1996-2006Chairwoman of the Liaison Committee and director of the Confederation Europeenne des Industries Agro-Alimentaires (CIAA).1996-2006Director of Tate & Lyle Plc (United Kingdom).1998-2004Director of Spadel (Belgium).1994-2000Chief Executive Officer of Amylum France, then Chairwoman of Amylum Group.1991-1994General Counsel of Gardini & Associés.1985-1991Attorney at Proskauer, Rose (New York) and Shearman & Sterling (Paris) with practice in mergers and acquisitions. - Carole Piwnica自2009年9月一直是董事会的成员。自2008年1月，Piwnica女士担任纳索斯英国公司的董事，该公司是一家为私人股本给出建议的咨询公司。之前，1996年到2006年Piwnica女士担任Tate & Lyle公共有限公司的董事，2000年到2006年担任政务副主席，该公司是欧洲食品和农业原料公司。1996年到2000年，她成为Amylum Group公司主席，该公司是Tate & Lyle公共有限公司欧洲地区的食品配料公司和分公司。2003年5月到2011年12月，Piwnica女士是英杰华公共有限公司董事会成员，该公司是一家英国保险公司；2006年5月到2009年10月，担任孟山都生物技术咨询委员会的成员；2007年到2010年，成为Dairy Crest董事会成员；1996年到2010年，成为Toepfer Gmbh董事会成员；从2010年到2013年，成为比利时路易斯·德尔海兹零售（比利时）的董事会成员。2010年，她被任命为欧洲通信卫星公司（卫星、法国）和赛诺菲（药品、法国）的董事会成员。Piwnica女士获得布鲁塞尔大学法律学士学位和纽约大学法律硕士学位。自1985年她也成为美国纽约州律师协会的成员，1988年到2013年又成为法国巴黎律师协会的成员。根据她的跨国企业领导的经验和丰富的法律经验和公司管理经验，Piwnica女士在领导跨国农业加工企业中有助于管理团队和董事会，能够合理履行公司管理义务并作出最佳的表现。
- Carole Piwnica,Since 2018Managing Partner of Naxos S.A. Switzerland.2007- 2018Founder Director of Naxos UK Ltd United Kingdom.2003-2011Director, Chairwoman of the Corporate Responsibility Committee and member of the Compensation Committee of Aviva PlcUnited Kingdom.2007-2010Director of Dairy Crest PlcUnited Kingdom.1996-2010Director of Toepfer GmbH Germany.2006-2009Member of the Ethical Committee of Monsanto United States.2000-2006Chairwoman of the Export Commission and director of the Association Nationale des Industries Alimentaires (ANIA).2000-2006Director and Vice-Chairwoman of Tate & Lyle Plc for Governmental Affairs (United Kingdom).1996-2006Chairwoman of the Liaison Committee and director of the Confederation Europeenne des Industries Agro-Alimentaires (CIAA).1996-2006Director of Tate & Lyle Plc (United Kingdom).1998-2004Director of Spadel (Belgium).1994-2000Chief Executive Officer of Amylum France, then Chairwoman of Amylum Group.1991-1994General Counsel of Gardini & Associés.1985-1991Attorney at Proskauer, Rose (New York) and Shearman & Sterling (Paris) with practice in mergers and acquisitions.
- L. John Doerr
-
L. John Doerr自2013年4月以来服务于董事会。他自1980年以来是风险资本公司Kleiner Perkins Caufield & Byers的普通合伙人。他目前在全球科技公司Google, Inc.（NASDAQ：GOOG）和合成生物学公司Amyris, Inc.（NASDAQ：AMRS）的董事会任职。他之前从1996年到2010年是网上零售公司Amazon.com, Inc.的董事；从1990年到2007年是Intuit Inc.（业务和财务管理解决方案的提供商）的董事；从1998年到2008年是Move, Inc.（房地产媒体和技术解决方案的提供商）的董事。他获得哈佛大学商学院（Harvard Business School ）的工商管理硕士学位，莱斯大学（Rice University）的电气工程和计算机科学硕士学位和电机工程学士学位。
L. John Doerr,has served as one of Doordash, Inc. directors since March 2015. Mr. Doerr has been Chairman of Kleiner Perkins, or Kleiner, a venture capital firm, since March 2016, and was previously its General Partner since August 1980. He currently serves on the board of directors of Alphabet Inc., the parent holding company of Google, Inc. Mr. Doerr previously served as a director of Bloom Energy Corporation, a clean energy company, Zynga Inc., a social gaming company, QuantumScape Corporation, a renewable energy company, Coursera, an education tech company, and Amazon.com, Inc., an e-commerce company. He holds a B.S. in Electrical Engineering and an M.S. in Electrical Engineering and Computer Science from Rice University and an M.B.A. from Harvard Business School. - L. John Doerr自2013年4月以来服务于董事会。他自1980年以来是风险资本公司Kleiner Perkins Caufield & Byers的普通合伙人。他目前在全球科技公司Google, Inc.（NASDAQ：GOOG）和合成生物学公司Amyris, Inc.（NASDAQ：AMRS）的董事会任职。他之前从1996年到2010年是网上零售公司Amazon.com, Inc.的董事；从1990年到2007年是Intuit Inc.（业务和财务管理解决方案的提供商）的董事；从1998年到2008年是Move, Inc.（房地产媒体和技术解决方案的提供商）的董事。他获得哈佛大学商学院（Harvard Business School ）的工商管理硕士学位，莱斯大学（Rice University）的电气工程和计算机科学硕士学位和电机工程学士学位。
- L. John Doerr,has served as one of Doordash, Inc. directors since March 2015. Mr. Doerr has been Chairman of Kleiner Perkins, or Kleiner, a venture capital firm, since March 2016, and was previously its General Partner since August 1980. He currently serves on the board of directors of Alphabet Inc., the parent holding company of Google, Inc. Mr. Doerr previously served as a director of Bloom Energy Corporation, a clean energy company, Zynga Inc., a social gaming company, QuantumScape Corporation, a renewable energy company, Coursera, an education tech company, and Amazon.com, Inc., an e-commerce company. He holds a B.S. in Electrical Engineering and an M.S. in Electrical Engineering and Computer Science from Rice University and an M.B.A. from Harvard Business School.
- Frank Kung
-
Frank Kung，2006年3月起任公司董事会成员。他是Vivo Ventures, LLC （前BioAsia Investments）的创始成员，1997年2月起担任管理合伙人。此前，他是Genelabs Technologies, Inc.的联合创始人、主席、首席执行官，也是Cetus Immune Corporation （后被其母公司Cetus Corporation收购）的联合创始人。他在Emerging Company Governing Body of the Biotechnology Industry Organization （BIO）；Mt. Jade Science and Technology Association, West Coast； the Asian American Manufacturing Association；以及Nanjing King-friend Biochemical Pharmaceutical Co。等董事会任职。他也被美国卫生与公众服务部部长任命为国家生物技术政策委员会的投票成员。
Frank Kung is a founding member of Vivo Capital LLC “Vivo”, a healthcare focused investment firm founded in 1996 in Palo Alto, California, whose fund under management is an owner of greater than five percent of the Company’s outstanding common stock. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981 which was acquired by its parent company in 1983. In 1983 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991 and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of healthcare and biotechnology companies. - Frank Kung，2006年3月起任公司董事会成员。他是Vivo Ventures, LLC （前BioAsia Investments）的创始成员，1997年2月起担任管理合伙人。此前，他是Genelabs Technologies, Inc.的联合创始人、主席、首席执行官，也是Cetus Immune Corporation （后被其母公司Cetus Corporation收购）的联合创始人。他在Emerging Company Governing Body of the Biotechnology Industry Organization （BIO）；Mt. Jade Science and Technology Association, West Coast； the Asian American Manufacturing Association；以及Nanjing King-friend Biochemical Pharmaceutical Co。等董事会任职。他也被美国卫生与公众服务部部长任命为国家生物技术政策委员会的投票成员。
- Frank Kung is a founding member of Vivo Capital LLC “Vivo”, a healthcare focused investment firm founded in 1996 in Palo Alto, California, whose fund under management is an owner of greater than five percent of the Company’s outstanding common stock. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981 which was acquired by its parent company in 1983. In 1983 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991 and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of healthcare and biotechnology companies.
- Steven R. Mills
-
Steven R. Mills从2012年5月开始担任我司首席财务官。加入阿米瑞斯公司前，从2010年12月到2012年2月，Mills先生担任阿彻丹尼尔斯米德兰公司（Archer-Daniels-Midland Company，ADM）的业绩与增长部的高级执行副总裁，这是一家全球性的农业商品加工公司。在这之前，从2008年3月到2010年12月，他担任ADM的执行副总裁兼首席财务官。Mills先生于1979年加入ADM，并担任多个高级会计与财政职位，包括担任12年的财务总管。他从2011年10月开始一直担任黑山公司（Black Hills Corporation）的董事与审计委员会委员，这是一家多元化的能源控股公司。Mills先生还担任伊利诺伊学院（Illinois College）与Hickory Point Bank & Trust的董事。他在伊利诺伊州杰克逊维尔市的伊利诺伊学院（Illinois College）获得数学理学士学位。
Steven R. Mills is a member of the Board of Directors of Amyris, Inc., a renewable products company, where he serves as Chair of the Audit Committee and as a member of the Leadership, Development, Inclusion and Compensation Committee. Mr. Mills is also a consultant and advisor to Arianna S.A., a European-based specialized investment fund. Previously, Mr. Mills served as Chief Financial Officer of Amyris, Inc. from 2012 to 2013. Prior to joining Amyris, he had a 33-year career at Archer Daniels Midland Company, one of the world's largest agricultural processors and food ingredient providers, where he held various senior executive roles, including Senior Executive Vice President Performance and Growth, Chief Financial Officer, Controller, and Senior Vice President Strategic Planning. - Steven R. Mills从2012年5月开始担任我司首席财务官。加入阿米瑞斯公司前，从2010年12月到2012年2月，Mills先生担任阿彻丹尼尔斯米德兰公司（Archer-Daniels-Midland Company，ADM）的业绩与增长部的高级执行副总裁，这是一家全球性的农业商品加工公司。在这之前，从2008年3月到2010年12月，他担任ADM的执行副总裁兼首席财务官。Mills先生于1979年加入ADM，并担任多个高级会计与财政职位，包括担任12年的财务总管。他从2011年10月开始一直担任黑山公司（Black Hills Corporation）的董事与审计委员会委员，这是一家多元化的能源控股公司。Mills先生还担任伊利诺伊学院（Illinois College）与Hickory Point Bank & Trust的董事。他在伊利诺伊州杰克逊维尔市的伊利诺伊学院（Illinois College）获得数学理学士学位。
- Steven R. Mills is a member of the Board of Directors of Amyris, Inc., a renewable products company, where he serves as Chair of the Audit Committee and as a member of the Leadership, Development, Inclusion and Compensation Committee. Mr. Mills is also a consultant and advisor to Arianna S.A., a European-based specialized investment fund. Previously, Mr. Mills served as Chief Financial Officer of Amyris, Inc. from 2012 to 2013. Prior to joining Amyris, he had a 33-year career at Archer Daniels Midland Company, one of the world's largest agricultural processors and food ingredient providers, where he held various senior executive roles, including Senior Executive Vice President Performance and Growth, Chief Financial Officer, Controller, and Senior Vice President Strategic Planning.
高管简历
中英对照 | 中文 | 英文- Han Kieftenbeld
自2016年4月以来，Han Kieftenbeld一直是Innophos的高级副总裁和首席财务官。从2014年6月到2015年7月，Kieftenbeld先生担任AB Mauri的全球首席财务官，AB Mauri是面包店配料的全球领导者。从2010年12月到2014年6月，Kieftenbeld先生担任Ingredion Incorporated的全球首席采购官，这是一家全球领先的成分解决方案提供商。在此之前，Kieftenbeld先生从2007年到2010年担任Akzonobel N.V.的首席财务官，在此之前，从1997年到2007年担任ICI plc的副总裁。目前，Kieftenbeld先生担任Themis Analytics的非执行顾问和董事会成员，这是一家为制药业提供销售与市场营销决策分析解决方案的国际公司。Kieftenbeld先生在纽约大学斯特恩商学院（New York University Stern School of Business）、伦敦政治经济学院（London School of Economics and Political Science）以及巴黎高等商学院（HEC School of Management）获得硕士学位。他持有荷兰温德海姆大学（Windesheim University）的商业经济和会计学士学位。
Han Kieftenbeld has served as our Chief Financial Officer since March 2020 and our Chief Administration Officer since July 2020. Mr. Kieftenbeld has over 25 years of international business leadership, finance and operations experience in food, health and nutrition end-markets. Previously, from April 2016 to April 2019 Mr. Kieftenbeld served as Senior Vice President and Chief Financial Officer of Innophos Holdings, Inc., a leading international science-based producer of essential ingredients for health and nutrition, food and beverage and industrial brands. From June 2014 to July 2015 Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide leader in bakery ingredients. Prior to that, Mr. Kieftenbeld held finance and operations roles of increasing reach and impact, including serving as Global Chief Procurement Officer of Ingredion Incorporated, and Global Chief Financial Officer of National Starch. Mr. Kieftenbeld started his career at Unilever in the Netherlands. In 2006 Mr. Kieftenbeld earned a joint Master of Business Administration degree from New York University Stern School of Business, London School of Economics and Political Science, and the HEC School of Management, Paris. He holds a Bachelor of Science degree in Business Economics and Accounting from Windesheim University in the Netherlands.- 自2016年4月以来，Han Kieftenbeld一直是Innophos的高级副总裁和首席财务官。从2014年6月到2015年7月，Kieftenbeld先生担任AB Mauri的全球首席财务官，AB Mauri是面包店配料的全球领导者。从2010年12月到2014年6月，Kieftenbeld先生担任Ingredion Incorporated的全球首席采购官，这是一家全球领先的成分解决方案提供商。在此之前，Kieftenbeld先生从2007年到2010年担任Akzonobel N.V.的首席财务官，在此之前，从1997年到2007年担任ICI plc的副总裁。目前，Kieftenbeld先生担任Themis Analytics的非执行顾问和董事会成员，这是一家为制药业提供销售与市场营销决策分析解决方案的国际公司。Kieftenbeld先生在纽约大学斯特恩商学院（New York University Stern School of Business）、伦敦政治经济学院（London School of Economics and Political Science）以及巴黎高等商学院（HEC School of Management）获得硕士学位。他持有荷兰温德海姆大学（Windesheim University）的商业经济和会计学士学位。
- Han Kieftenbeld has served as our Chief Financial Officer since March 2020 and our Chief Administration Officer since July 2020. Mr. Kieftenbeld has over 25 years of international business leadership, finance and operations experience in food, health and nutrition end-markets. Previously, from April 2016 to April 2019 Mr. Kieftenbeld served as Senior Vice President and Chief Financial Officer of Innophos Holdings, Inc., a leading international science-based producer of essential ingredients for health and nutrition, food and beverage and industrial brands. From June 2014 to July 2015 Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide leader in bakery ingredients. Prior to that, Mr. Kieftenbeld held finance and operations roles of increasing reach and impact, including serving as Global Chief Procurement Officer of Ingredion Incorporated, and Global Chief Financial Officer of National Starch. Mr. Kieftenbeld started his career at Unilever in the Netherlands. In 2006 Mr. Kieftenbeld earned a joint Master of Business Administration degree from New York University Stern School of Business, London School of Economics and Political Science, and the HEC School of Management, Paris. He holds a Bachelor of Science degree in Business Economics and Accounting from Windesheim University in the Netherlands.
- Eduardo Alvarez
Eduardo Alvarez自2017年10月起担任我们的首席运营官。Alvarez先生拥有超过30年的运营和建议成长型公司的全球运营经验。此前，他曾担任普华永道会计师事务所（PricewaterhouseCoopers LLP PwC）的全球运营战略领导人。任职期间，Alvarez先生联合领导了他之前的公司Booz&Company的整合，该公司被普华永道（PwC）收购。在该职位上，他将运营发展为全球业务，拥有15亿美元的收入和4000名员工。Alvarez先生的工作重点是改善结构成本，同时推动持续的收入增长。他的经验还包括在Booz Allen Hamilton，General Electric和AT&T的角色。Alvarez持有Harvard Business School工商管理硕士学位、University of California Berkeley计算机控制和制造机械工程理学硕士学位以及University of Michigan机械工程理学学士学位。Alvarez先生是Chicago Council of Global Affairs的董事会成员。
Eduardo Alvarez has served as our Chief Operating Officer since October 2017. Mr. Alvarez has over 30 years of global operations experience both running and advising growth companies. Previously, he served as Global Operations Strategy Leader for PricewaterhouseCoopers LLP PwC. During his tenure, Mr. Alvarez co-led the integration of his prior company, Booz & Company, following its acquisition by PwC. In that role, he grew operations into a global practice with $1.5 billion in revenue and 4000 employees. Mr. Alvarez’s assignments focused on delivering structural cost improvements while also driving sustained revenue growth. His experience also includes roles at Booz Allen Hamilton, General Electric and AT&T. Alvarez holds a Master of Business Administration degree from Harvard Business School, a Master’s of Science in Mechanical Engineering in Computer Control and Manufacturing from the University of California, Berkeley, and a Bachelor of Science degree in Mechanical Engineering from the University of Michigan. Mr. Alvarez is a board member of The Chicago Council of Global Affairs.- Eduardo Alvarez自2017年10月起担任我们的首席运营官。Alvarez先生拥有超过30年的运营和建议成长型公司的全球运营经验。此前，他曾担任普华永道会计师事务所（PricewaterhouseCoopers LLP PwC）的全球运营战略领导人。任职期间，Alvarez先生联合领导了他之前的公司Booz&Company的整合，该公司被普华永道（PwC）收购。在该职位上，他将运营发展为全球业务，拥有15亿美元的收入和4000名员工。Alvarez先生的工作重点是改善结构成本，同时推动持续的收入增长。他的经验还包括在Booz Allen Hamilton，General Electric和AT&T的角色。Alvarez持有Harvard Business School工商管理硕士学位、University of California Berkeley计算机控制和制造机械工程理学硕士学位以及University of Michigan机械工程理学学士学位。Alvarez先生是Chicago Council of Global Affairs的董事会成员。
- Eduardo Alvarez has served as our Chief Operating Officer since October 2017. Mr. Alvarez has over 30 years of global operations experience both running and advising growth companies. Previously, he served as Global Operations Strategy Leader for PricewaterhouseCoopers LLP PwC. During his tenure, Mr. Alvarez co-led the integration of his prior company, Booz & Company, following its acquisition by PwC. In that role, he grew operations into a global practice with $1.5 billion in revenue and 4000 employees. Mr. Alvarez’s assignments focused on delivering structural cost improvements while also driving sustained revenue growth. His experience also includes roles at Booz Allen Hamilton, General Electric and AT&T. Alvarez holds a Master of Business Administration degree from Harvard Business School, a Master’s of Science in Mechanical Engineering in Computer Control and Manufacturing from the University of California, Berkeley, and a Bachelor of Science degree in Mechanical Engineering from the University of Michigan. Mr. Alvarez is a board member of The Chicago Council of Global Affairs.
- Nicole Kelsey
Nicole Kelsey自2017年8月起担任我们的总法律顾问兼秘书。她的专业领域包括美国证券法，国际并购和公司治理。在加入Amyris之前，她在巴黎担任了全球商业营销的全球领导者Criteo的总法律顾问和秘书超过三年。在加入Criteo之前，Kelsey女士是全球医疗技术领导者美敦力公司的高级证券律师。她曾担任CIT Group，Inc。的首席并购律师。是一家私人商人银行的总顾问；并为国际企业集团维旺迪（Vivendi）工作。在进入公司内部之前，凯尔西女士曾在巴黎和纽约的White＆Case和Willkie，Farr＆Gallagher律师事务所执业。 Kelsey女士是富布赖特大学的学者，拥有西北大学的法学博士学位和学士学位。来自俄亥俄州立大学。
Nicole Kelsey has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise.- Nicole Kelsey自2017年8月起担任我们的总法律顾问兼秘书。她的专业领域包括美国证券法，国际并购和公司治理。在加入Amyris之前，她在巴黎担任了全球商业营销的全球领导者Criteo的总法律顾问和秘书超过三年。在加入Criteo之前，Kelsey女士是全球医疗技术领导者美敦力公司的高级证券律师。她曾担任CIT Group，Inc。的首席并购律师。是一家私人商人银行的总顾问；并为国际企业集团维旺迪（Vivendi）工作。在进入公司内部之前，凯尔西女士曾在巴黎和纽约的White＆Case和Willkie，Farr＆Gallagher律师事务所执业。 Kelsey女士是富布赖特大学的学者，拥有西北大学的法学博士学位和学士学位。来自俄亥俄州立大学。
- Nicole Kelsey has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise has served as our General Counsel and Secretary since August 2017. Ms. Kelsey has over 25 years of experience as an executive leader for public companies with international operations. Her areas of expertise.
- John Melo
John Melo作为全球燃料行业和技术创新领域的企业家和思想领导，John Melo拥有近30年的综合经验。Melo先生自2007年1月起担任Amyris, Inc.的首席执行官和董事，自2008年6月起担任Amyris, Inc.总裁。在加入Amyris之前，Melo先生于1997年至2006年在BP plc（前身为British Petroleum）担任多个高级管理职位，BP plc是世界上最大的能源公司之一，最近担任美国燃料业务总裁。在BP任职期间，Melo先生还担任炼油和营销部门的首席信息官、BP首席执行官Lord Browne的电子商务战略高级顾问和全球品牌发展总监。在加入BP之前，Melo先生曾在会计师事务所Ernst & Young任职，并担任多家初创公司的管理团队成员，包括管理系统集成公司Computer Aided Services和汽车维修软件提供商Alldata Corporation到汽车服务行业。Melo先生目前在Renmatix，Inc.、生物技术创新组织的工业和环境部门以及加州生命科学协会的董事会任职。Melo先生曾被任命为美国-巴西CEO论坛美国部分的成员。
John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as Amyris, Inc. CEO and a director since January 2007 and as Amyris, Inc. President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc formerly British Petroleum, one of the world's largest energy firms, from 1997 to 2006 most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.- John Melo作为全球燃料行业和技术创新领域的企业家和思想领导，John Melo拥有近30年的综合经验。Melo先生自2007年1月起担任Amyris, Inc.的首席执行官和董事，自2008年6月起担任Amyris, Inc.总裁。在加入Amyris之前，Melo先生于1997年至2006年在BP plc（前身为British Petroleum）担任多个高级管理职位，BP plc是世界上最大的能源公司之一，最近担任美国燃料业务总裁。在BP任职期间，Melo先生还担任炼油和营销部门的首席信息官、BP首席执行官Lord Browne的电子商务战略高级顾问和全球品牌发展总监。在加入BP之前，Melo先生曾在会计师事务所Ernst & Young任职，并担任多家初创公司的管理团队成员，包括管理系统集成公司Computer Aided Services和汽车维修软件提供商Alldata Corporation到汽车服务行业。Melo先生目前在Renmatix，Inc.、生物技术创新组织的工业和环境部门以及加州生命科学协会的董事会任职。Melo先生曾被任命为美国-巴西CEO论坛美国部分的成员。
- John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as Amyris, Inc. CEO and a director since January 2007 and as Amyris, Inc. President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc formerly British Petroleum, one of the world's largest energy firms, from 1997 to 2006 most recently as President of U.S. Fuels Operations. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, and Director of Global Brand Development. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of Renmatix, Inc., the Industrial and Environmental section of the Biotechnology Innovation Organization, and the California Life Sciences Association. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum.